Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review).

@article{Ibrahim2012MolecularTT,
  title={Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review).},
  author={Nuha Ibrahim and Yan Yu and William Robert Walsh and Jia-lin Yang},
  journal={Oncology reports},
  year={2012},
  volume={27 5},
  pages={1303-11}
}
Sorafenib is an oral multikinase inhibitor that acts by inhibiting tumor growth and disrupting tumor microvasculature through antiproliferative, anti-angiogenic and proapoptotic effects. It exerts these effects via inhibition of multiple targets including Raf serine/threonine kinases, vascular endothelial growth factor receptor tyrosine kinases; VEGFR-1, VEGFR-2, VEGFR-3 and platelet-derived growth factor receptor β (PDGFR-β). Current… CONTINUE READING